As of close of business last night, Arbutus Biopharma Corp’s stock clocked out at $2.97, up 2.06% from its previous closing price of $2.91. On the day, 3625999 shares were traded.
Ratios:
To gain a deeper understanding of ABUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.87 and its Current Ratio is at 5.87. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 02 ’24 when McElhaugh Michael J. sold 10,164 shares for $2.31 per share. The transaction valued at 23,504 led to the insider holds 1,504,793 shares of the business.
Sofia Michael J. sold 9,982 shares of ABUS for $23,083 on Feb 02 ’24. The Chief Scientific Officer now owns 1,485,121 shares after completing the transaction at $2.31 per share. On Feb 02 ’24, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 29.39 while its Price-to-Book (P/B) ratio in mrq is 4.76.
Stock Price History:
Over the past 52 weeks, ABUS has reached a high of $3.29, while it has fallen to a 52-week low of $1.69.
Shares Statistics:
A total of 169.87M shares are outstanding, with a floating share count of 136.99M. Insiders hold about 23.68% of the company’s shares, while institutions hold 43.84% stake in the company.
Earnings Estimates
As of right now, Alpha Blue Capital US Small-Mid analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $2.97, with high estimates of $16.84 and low estimates of $2.05.
Analysts are recommending an EPS of between $Healthcare and $Communication Services for the fiscal current year, implying an average EPS of $Healthcare.
